Article first published online: 13 NOV 2008
Copyright © 2008 American Association for the Study of Liver Diseases
Volume 49, Issue 3, pages 729–738, March 2009
How to Cite
George, S. L., Bacon, B. R., Brunt, E. M., Mihindukulasuriya, K. L., Hoffmann, J. and Di Bisceglie, A. M. (2009), Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients. Hepatology, 49: 729–738. doi: 10.1002/hep.22694
This work was presented in part at the 13th International Conference on Hepatitis C and Related Flaviviviruses, August 2006, Cairns, Australia, and at the annual meeting of the American Association for the Study of Liver Diseases, October 2006, Boston, MA.
Potential conflict of interest: Dr. Bacon is a consultant for, is on the speakers' bureau of, and received grants from Schering Plough. He received grants from Roche and Bristol-Myers Squibb. He is on the speakers' bureau of Gilead Sciences and Three Rivers. He received grants from and is a consultant for Coley Pharmaceuticals, ISIS, and Valeant. He advises and received grants from GlaxoSmithKline. Dr. Brunt received grants from Roche. Dr. Di Bisceglie is a consultant for Schering-Plough. He is also a consultant for, advises, and received grants from Roche.
- Issue published online: 24 FEB 2009
- Article first published online: 13 NOV 2008
- Accepted manuscript online: 13 NOV 2008 12:00AM EST
- Manuscript Accepted: 8 OCT 2008
- Manuscript Received: 14 AUG 2008
- Merit Review grant from the Department of Veteran's Affairs
- National Institutes of Health Grant. Grant Number: DK41816
- Saint Louis University Liver Center Grant
- Schering Plough
- 1Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426–1432., , , , , , et al.
- 19Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival. Scand J Gastroenterol 2005; 40: 688–696., , , , , , et al.